Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1998-08-05
2000-05-02
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514561, 514810, 514812, 514813, A01N 3712
Patent
active
060573686
ABSTRACT:
The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a primate suffering from substance addiction. The method includes administering to a primate an effective amount of a pharmaceutical composition including gamma vinylGABA. The present invention also provides a method of treatment of nicotine addiction by treating a patient with an effective amount of a composition including gamma vinylGABA.
REFERENCES:
patent: 4540582 (1985-09-01), Seiler et al.
patent: 4595697 (1986-06-01), Seiler et al.
patent: 4621145 (1986-11-01), Frieben et al.
patent: 5189064 (1993-02-01), Blum et al.
Morgan et al., "Longterm Cocaine Administration May Alter Specific Gabergic Pathways", Abstracts Society for Neuroscience, 23:1942 (1997).
Kushner et al., "Comparison of the Effects of Vigabatrin on Cocaine Self-Administration and Food Reinforcement", Abstracts Society for Neuroscience, 23:1942 (1997).
Dewey et al., "GABAergic Attenuation of Cocaine-Induced Dopamine Release and Locomotor Activity", Synapse, 25:393-398 (1997).
Morgan et al., "Effects of Pharmacologic Increases in Brain GABA Levels on Cocaine-Induced Changes in Extracellular Dopamine", Synapse 28:60-65 (1998).
Kushner et al., "Gamma-vinyl GABA Attenuates Cocaine-Induced Lowering of Brain Stimulation Reward Thresholds", Psychopharmacology 133:383-388 (1997).
Porter et al., "Antiepileptic Drugs", Basic and Clinical Pharmacology, ed. by Katzung, B.G., Appelton and Lange, Stamford, CT pp. 386-408 (1998).
Takada et al., "Drug Dependence Study on Vigabatrin in Rhesus Monkeys and Rats", Arzneim.-Forsch.'Drug Res 47(II), 1087-1092 (1997).
Nisell et al., "Nicotine Dependence, Midbrain Dopamine Systems and Psychiatric Disorders", Pharmacology & Toxicology 76:157-162 (1995).
Nisell et al., "Infusion of Nicotine in the Ventral Tegmental Area or the Nucleus Accumbens of the Rat Differentially Affects Accumbal Dopamine Release", Pharmacology & Toxicology, 75:348-352 (1994).
Fudala et al., "Pharmacologic Characterization of Nicotine-Induced Conditioned Place Preference", Pharmacol Biochem Behav 22(2) 237-241 (1985).
Clarke et al., "Apparent Absence of Nicotine-Induced Conditioned Place Preference in Rats" Psychopharmacology, 92: 84-88 (1987).
Clarke et al., " Evidence That Mesolimbic Dopaminergic Activation Underlies the Locomotor Stimulant Action of Nicotine in Rats", The Journal of Pharmacology and Experimental Therapeutics, 246:701-708 (1988).
Henningfield et al., "Control of Behavior by Intravenous Nicotine Injections in Human Subjects", Pharmacology Biochemistry & Behavior, 19:1021-1026 (1983).
Jarvik et al., "Pharmacological Treatment of Tobacco Dependence", Pharmacology Biochemistry & Behavior, 30:279-294 (1988).
Henningfield et al., "Cigarette Smokers Self-Administer Intravenous Nicotine", Pharmacology Biochemistry & Behavior 19:887-890 (1983).
Nisell et al., "Systemic Nicotine-Induced Dopamine Release in the Rat Nucleus Accumbens is Regulated by Nicotinic Receptors in the Ventral Tegmental Area", Synapse 16:36-44 (1994).
Pontieri et al., "Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs" Nature 382:255-257 (1996).
Di Chiara et al., "Drugs Abused by Humans Preferentially Increase Synaptic Dopamine Concentrations in the Mesolimbic System of Freely Moving Rats", Proc. Natl. Acad. Sci. USA, 85:5274-5278 (1988).
Damsma et al., "Lack of Tolerance to Nicotine-Induced Dopamine Release in the Nucleus Accumbens", European Journal of Pharmacology, 168:363-368 (1989).
Imperato et al., "Nicotine Preferentially Stimulates Dopamine Release in the Limbic System for Freely Moving Rats" European Journal of Pharmacology, 132:337-338 (1986).
Brazell et al., "Acute Administration of Nicotine Increases the In Vivo Extracellular Levels of Dopamine, 3,4-Dihydroxyphenylacetic Acid and Ascorbic Acid Preferentially in the Nucleus Accumbens of the Rat: Comparison with Caudate-Putamen", Neuropharmacology 29:1177-1185 (1990).
Horan et al., "Nicotine Produces Conditioned Place Preference in Lewis But Not Fischer 344 Rats", Synapse 26:93-94 (1997).
Lepore et al., "Conditioned Place Preference Induced By .DELTA..sup.9 -Tetrahydrocannabinol: Comparison with Cocaine, Morphine, and Food Reward", Life Sciences, 56:2073-2080 (1995).
Sora et al., "Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice" Proc. Natl. Acad. Sci. USA 95:7699-7704 (1998).
Valentine et al., "Self-Administration in Rats Allowed Unlimited Access to Nicotine" Psychopharmacology, 133:300-305 (1997).
Eliot L. Gardner, "6 Brain Reward Mechanisms", Substance Abuse: A Comprehensive Textbook, pp. 51-85 (1997).
Marshall et al., "Presynaptic Nicotinic Modulation of Dopamine Release in the Three Ascending Pathways Studied by In Vivo Microdialysis: Comparison of Naive and Chronic Nicotine-Treated Rats" Journal of Neurochemistry, 68:1511-1519 (1997).
M.-F. Chesselet, "Presynaptic Regulation of Neurotransmitter Release in the Brain", Neuroscience 12:347-375 (1984).
Lacey et al., "On the Potassium Conductance Increase Activated by GABA.sub.B and Dopamine D.sub.2 Receptors in Rat Substantia Nigra Neurones" Journal of Physiology 401:437-453 (1988).
Grant et al., "Vigabatrin: A Review of its Pharmacodynamic an Pharmacokinetic Properties, and Therapeutic Potential in Epilepsy and Disorders of Motor Control" Drugs 41 6:889-926 (1991).
Jung et al., "Vinyl GABA (4-amino-hex-5-enoic acid). A New Selective Irreversible Inhibitor of GABA-T: Effects on Brain GABA Metabolism in Mice" Neurochem. 29:797-802 (1977).
Tsuji et al., "Activation of Ventral Tegmental GABA.sub.B Receptors Inhibits Morphine-Induced Place Preference in Rats" European Journal of Pharmacology 313:169-173.
Roberts et al., "Baclofen Suppression of Cocaine Self-Administration: Demonstration Using a Discrete Trials Procedure" Psychopharmacology 131:271-277 (1997).
Bolser et al., "The Pharmacology of SCH 50911: A Novel, Orally-Active GABA-B Receptor Antagonist" The Journal of Pharmacology and Experimental Therapeutics 274:1393-1398 (1995).
Roberts et al., "Baclofen Attenuates the Reinforcing Effects of Cocaine in Rats" Neuropsychopharmacology 15:417-423 (1996).
Derek van der Kooy, "Place Conditioning: A Simple and Effective Method for Assessing the Motivational Properties of Drugs" M.A. Bozarth, Ed., Springer-Verlag, New York, pp. 229-241 (1987).
Hurt et al., "A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation" The New England Journal of Medicine 337:1195-1202 (1997).
Volkow et al., "Imaging Endogenous Dopamine Competition With [.sup.11 C] Raclopride in the Human Brain" Synapse 16:255-262 (1994).
Logan et al., "Graphical Analysis of Reversible Radioligand Binding from Time-Activity Measurements Applied to [N-.sup.11 C-methyl]-(-)-Cocaine PET Studies in Human Subjects" Journal of Cerebral Blood Flow and Metabolism 10:740-747 (1990).
Dewey et al., "A Novel Strategy for the Treatment of Cocaine Addiction" Synapse 30:119-129 (1998).
Dewey et al., "Striatal Binding of the PET Ligand .sup.11 C-Raclopride is Altered by Drugs that Modify Synaptic Dopamine Levels" Synapse 13:350-356 (1993).
Dewey et al. "GABAergic Inhibition of endogenous Dopamine Release Measured in vivo with .sup.11 C-Raclopride and Positron Emission Tomography" The Journal of Neuroscience 12(10):3773-3780 (1992).
Dewey et al., "Effects of Central Cholinergic Blockade on Striatal Dopamine Release Measured with Positron Emission Tomography in Normal Human Subjects" Proc. Natl. Acad. Sci. USA 90:11816-11820 (1993).
Buckland et al., "Amphetamine and Vigabatrin Down Regulate Aromatic L-amino acid Decarboxylase mRNA levels" Molecular Brain Research 35:69-76 (1996).
Cubells et al., "In Vivo Action of Enzyme-Activated Irreversible Inhibitors of Glutamic Acid Decarboxylase and .gamma.-Aminobutyric Acid Transaminase in Retina vs. Brain" The Journal of Pharmacology and Experimental Therapeutics 238:508-514 (1986).
Herbert D. Kleber, "Treatment of Cocaine Abuse: Pharmacotherapy" Cocaine Scientific and
Ashby, Jr. Charles R.
Brodie Jonathan D.
Dewey Stephen L.
Bogosian Margaret C.
Brookhaven Science Associates LLC
MacMillan Keith D.
LandOfFree
Treatment of addiction and addiction-related behavior does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of addiction and addiction-related behavior, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of addiction and addiction-related behavior will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1594383